Thanks to its COVID shots and its COVID infection antiviral treatment, Paxlovid, Pfizer has marked a record high in its quarterly sales. In all, the company’s revenue increased by 47%, top $27.7 billion in 2021.
It’s expecting even more in 2022, with an anticipated $32 billion incoming from its COVID jab and $22 billion for Paxlovid.
SOURCE:
CNBC July 28, 2022